Strides Pharma Science Limited — Board Meeting, 31-10-2025: Outcome of Board Meeting
31-10-2025 | 12:58 pm
31-10-2025 | 12:58 pm
Strides Pharma's board approved the financial results for the quarter and half-year. Consolidated revenue from operations for H1 reached ₹2,340.57 Cr, with Profit After Tax at ₹237.12 Cr. Performance reflects ongoing business trajectory. #StridesPharma
No comments yet. Be the first to comment!
